Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

Liv B. Gansmo; Lars Vatten; Pål Romundstad; Kristian Hveem; Bríd M. Ryan; Curtis C. Harris; Stian Knappskog; Per E. Lønning

doi:10.18632/oncotarget.8705

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

Liv B. Gansmo, Lars Vatten, Pål Romundstad, Kristian Hveem, Bríd M. Ryan, Curtis C. Harris, Stian Knappskog and Per E. Lønning _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:28637-28646. https://doi.org/10.18632/oncotarget.8705

Metrics: PDF 1569 views | HTML 2186 views | ?

Abstract

Liv B. Gansmo1,2, Lars Vatten3, Pål Romundstad3, Kristian Hveem3, Bríd M. Ryan4, Curtis C. Harris4, Stian Knappskog1,2, Per E. Lønning1,2

1Section of Oncology, Department of Clinical Science, University of Bergen, Bergen, Norway

2Department of Oncology, Haukeland University Hospital, Bergen, Norway

3Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway

4Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Correspondence to:

Per E. Lønning, e-mail: [email protected]

Keywords: MDM2, polymorphism, del1518, SNP309, cancer risk

Received: February 16, 2016 Accepted: March 28, 2016 Published: April 12, 2016

ABSTRACT

The MDM2 promoter region contains several polymorphisms, some of which have been associated with MDM2 expression, cancer risk and age at cancer onset. del1518 (rs3730485) is an indel polymorphism residing in the MDM2 promoter P1 and is in almost complete linkage disequilibrium with the MDM2 promoter P2 polymorphism SNP309T>G (rs2279744). Cancer risk assessments of del1518 have previously been conducted in relatively small Chinese populations only. In this study we assessed the genotype distribution of del1518 among healthy Caucasians, African Americans and Chinese, and we estimated the Odds Ratios (OR) for incident cancer of the breast, colon, lung and prostate (n=7,081) as compared to controls (n=3,749) in a large Caucasian (Norwegian) cohort.

We found the genotypes of the del1518 to vary significantly between healthy Caucasians, African-Americans and Chinese (p< 1×10^-5). Further, we found a positive association of the del1518 del-allele with risk of colon cancer (dominant model: OR = 1.15; 95 % CI = 1.01 – 1.31). Stratifying according to SNP309 status, this association remained among carriers of the SNP309TG genotype (OR = 1.21; 95 % CI = 1.01 – 1.46), but with no clear association among carriers of the SNP309TT genotype. In conclusion, our findings suggest del1518 to be associated with increased risk of colon cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8705

Publication Alerts

Research Papers:

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

Abstract